Please enable Javascript
Zachary Bessette
Zachary Bessette
Articles by Zachary Bessette
The Future of Personalized Care in Oligometastatic Prostate Cancer
Zachary Bessette
mHSPC
|
January 31, 2023
Dr. Deek shares what research should be done to better personalize care for patients with oligometastatic prostate cancer.
View More
High-Risk Mutations in Oligometastatic Prostate Cancer Patients
Zachary Bessette
mHSPC
|
January 31, 2023
Dr. Deek shares what “high-risk mutation” signified in his study and how patients with “high-risk mutation” should be ...
View More
PSMA Imaging in Oligometastatic Prostate Cancer
Zachary Bessette
Next-Generation Imaging
|
January 31, 2023
Dr. Deek shares how PSMA imaging used in both the STOMP and ORIOLE trials.
View More
MDT in omCSPC in the ORIOLE and STOMP Trials
Zachary Bessette
mHSPC
|
January 31, 2023
Dr. Deek shares how he evaluated long-term outcomes of MDT in om CSPC in both the ORIOLE and STOMP trials.
View More
Joshua Meeks, MD, PhD – Targeting Unmet Need in Urothelial Carcinoma
Joshua Meeks, MD, PhD
Non-Muscle Invasive Urothelial Carcinoma
|
January 27, 2023
Joshua Meeks, MD, PhD, discusses ongoing research in NMIBC and the future of urothelial carcinoma care.
Read More
Total Intracorporeal Versus Open Bladder Cuffing in Robotic Radical Nephroureterectomy for UTUC
Zachary Bessette
Upper Tract Urothelial Carcinoma
|
January 25, 2023
Intracorporeal DUBC may be a safe and effective alternative to RNU for UTUC, according to a new research.
Read More
RLT-PSMA in Development
Zachary Bessette
Next-Generation Imaging
|
January 24, 2023
Dr. Ulaner highlights the line(s) of therapy in which novel RLT-PSMA agents are being developed.
View More
Safety and Efficacy of 177Lu-PSMA-617
Zachary Bessette
Next-Generation Imaging
|
January 24, 2023
Dr. Ulaner explains the data that led to the FDA approval of 177Lu-PSMA-617 and the safety profile of this drug.
View More
Molecular Imaging and Therapy in Prostate Cancer
Zachary Bessette
Next-Generation Imaging
|
January 24, 2023
Dr. Ulaner details the current application and capabilities of molecular imaging in prostate cancer.
View More
Novel PRO Tool for Patients With Prostate Cancer After Radionuclide Therapy
Zachary Bessette
Phenotypic Precision Medicine in Advanced Prostate Cancer
|
January 23, 2023
Moffitt Cancer Center developed the first PRO measure for patients receiving RNT to guide treatment and improve QoC.
Read More